Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 12-2024 | 09-2024 | 06-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,634,105 | 2,415,055 | 3,261,232 | 5,755,400 | 5,147,341 |
| Marketable Securities | 395,706 | 477,252 | 215,299 | 316,240 | 341,670 |
| Receivables | 4,775,218 | 4,688,764 | 4,851,422 | 4,831,075 | 4,943,149 |
| Inventories | 8,836,505 | 8,560,664 | 8,226,418 | 8,083,088 | 8,171,129 |
| Other current assets | 1,218,686 | 1,198,805 | 1,623,919 | 1,476,087 | 1,284,921 |
| TOTAL | $19,860,220 | $17,340,540 | $18,178,290 | $20,461,890 | $19,888,210 |
| Non-Current Assets | |||||
| PPE Net | 13,492,060 | 13,498,260 | 13,317,320 | 12,647,050 | 13,346,440 |
| Investments And Advances | 2,545,458 | 2,395,128 | 2,707,360 | 1,858,004 | 2,861,958 |
| Intangibles | 59,370,280 | 60,157,050 | 62,529,400 | 59,835,900 | 64,639,080 |
| Other Non-Current Assets | 3,130,022 | 3,240,332 | 2,972,790 | 2,836,246 | 3,121,472 |
| TOTAL | $78,537,820 | $79,290,770 | $81,526,870 | $77,177,200 | $83,968,950 |
| Total Assets | $98,398,040 | $96,631,300 | $99,705,170 | $97,639,100 | $103,857,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,998,234 | 2,560,887 | 894,082 | 4,181,477 | 2,807,955 |
| Accounts payable and accrued liabilities | 2,985,098 | 2,907,025 | 3,037,195 | 2,769,344 | 3,000,845 |
| Other current liabilities | 8,730,554 | 8,460,573 | 8,862,889 | 8,096,019 | 8,930,412 |
| TOTAL | $14,549,650 | $14,970,140 | $13,846,560 | $15,994,490 | $15,777,290 |
| Non-Current Liabilities | |||||
| Long Term Debt | 29,589,940 | 28,530,110 | 31,050,890 | 29,661,520 | 32,270,350 |
| Other Non-Current Liabilities | 5,538,353 | 5,522,935 | 5,592,438 | 5,296,053 | 5,538,850 |
| TOTAL | $35,352,890 | $34,284,540 | $36,891,950 | $35,269,920 | $38,164,790 |
| Total Liabilities | $49,902,550 | $49,254,670 | $50,738,510 | $51,264,400 | $53,942,090 |
| Shareholders' Equity | |||||
| Common Shares | 11,524,360 | 11,693,510 | 11,184,760 | 11,354,220 | 10,730,210 |
| Retained earnings | 7,810,875 | 7,981,175 | 8,520,257 | 9,592,283 | 8,564,429 |
| Other shareholders' equity | 17,698,395 | 16,203,445 | 17,836,053 | 13,948,627 | 19,683,651 |
| TOTAL | $48,495,490 | $47,376,640 | $48,966,660 | $46,374,700 | $49,915,090 |
| Total Liabilities And Equity | $98,398,040 | $96,631,310 | $99,705,170 | $97,639,100 | $103,857,180 |